Picture three items on a desk: a semaglutide tablet, an orforglipron tablet and a dropper bottle advertised as an “oral GLP-1.” The first two have approved product labels. The third description tells you a proposed route and a drug-family claim, but little about the actual preparation. The labels reveal another surprise: one approved tablet contains a peptide; the other does not. “Oral GLP-1” is a starting description, not a complete scientific identity.
A tablet is more than its active ingredient
Wegovy's current prescribing information covers both injectable and tablet formulations of semaglutide, a peptide that activates the GLP-1 receptor. Its tablets contain salcaprozate sodium, known as SNAC, which facilitates absorption.[1] The label places most absorption of tablet semaglutide in the stomach and estimates absolute bioavailability at approximately 1%–2%.[1] Bioavailability describes the fraction reaching the circulation, not the percentage of people who benefit.
That small fraction is compatible with an effective medicine. The approved tablet has clinical evidence for weight reduction; low absorption does not by itself mean clinical failure.[1] Its 64-week tablet trial studied adults with obesity or overweight with a related condition, excluding people with type 2 diabetes.[1] It also does not support the claim that swallowed peptides universally have zero absorption. What the label establishes is narrower and more useful: this molecule, in this finished formulation, can reach the circulation and produce clinically evaluated effects.
A powder bearing the same molecule name does not reproduce the tablet's formulation. Neither does putting the molecule in a liquid automatically reproduce its absorption. The enhancer, formulation and supporting studies belong to the finished product. They cannot be transferred merely by changing the format named on a package.
Sharing a receptor does not mean sharing chemistry
Orforglipron, approved as Foundayo on April 1, 2026, is another oral GLP-1 receptor agonist.[4] Its chemical structure identifies it as a non-peptide small molecule; it is not an oral version of semaglutide.[2] “Agonist” describes activation of a receptor, while “peptide” describes a molecular structure. Those categories answer different questions.
FDA reports that two randomized, double-blind, placebo-controlled trials supported Foundayo's approval. These studies enrolled adults with obesity, or overweight with at least one weight-related condition. Over 72 weeks, study treatment alongside lifestyle intervention produced clinically meaningful weight reductions compared with placebo.[4] That is positive human evidence, not merely a theory that a receptor can be activated.
There is a useful formulation detail inside the label: the pivotal trials used an investigational orforglipron formulation, and the label presents their results in equivalent Foundayo amounts.[2] A clinical-trial preparation and a marketed tablet need not be physically identical, but the relationship must be established. The label's explicit connection is evidence for that product, not permission to assume equivalence for another preparation.
Wegovy and Foundayo also have different clinical programs. Their separate trial percentages cannot establish which performs better in a direct comparison. Differences in participants, study design and follow-up must be considered before ranking results from separate trials.
The distinctions that an “oral” claim leaves out
| Product or preparation | Relevant evidence | What that evidence cannot automatically establish |
|---|---|---|
| Wegovy tablet | Semaglutide with SNAC; formulation-specific absorption and clinical labeling [1] | Performance of a semaglutide drop, spray or powder |
| Wegovy injection | A separately described injectable semaglutide formulation [1] | Identical absorption or properties for an oral preparation |
| Foundayo tablet | Non-peptide orforglipron; approved labeling connects the trial formulation with the finished medicine [2] | Effects of peptide products or another orforglipron preparation |
| Compounded product | Product-specific information is needed; compounding is not FDA approval [3] | Automatic equivalence to an approved medicine |
| Research powder, or a separately marketed drop or spray | Exact identity, formulation and intended use must first be established | Human safety or effectiveness borrowed from another product's label |
This separation avoids two opposite mistakes. Approval of an oral medicine does not validate every oral claim. Equally, an unfamiliar format alone does not prove that the exact product has never been studied or is universally illegal. Those conclusions require evidence about the particular product and context. The sources reviewed here cannot supply a worldwide inventory of every drop or spray.
Effective medicines still have material risks
Both labels describe gastrointestinal adverse reactions, including nausea, vomiting and diarrhea, and warnings involving pancreatitis, severe gastrointestinal reactions and kidney injury associated with volume depletion.[1][2] A swallowed medicine can have effects throughout the body. Removing an injection does not remove pharmacological risks.
Their boxed thyroid warnings require especially careful reading. Semaglutide caused thyroid C-cell tumors in rodents; the relevance to humans remains undetermined.[1] Foundayo's warning describes receptor-dependent thyroid tumors observed with drugs active at rodent GLP-1 receptors. Orforglipron itself is not pharmacologically active in rats or mice and did not produce rodent tumors, but the label still states that the human relevance of the rodent class finding is undetermined.[2]
These are different animal observations alongside a shared unresolved human question. Neither proves that the medicines cause human thyroid cancer. The absence of tumors in an animal where orforglipron lacks receptor activity cannot settle safety at the human receptor either. The labels retain contraindications for specified thyroid-cancer histories and multiple endocrine neoplasia syndrome type 2.[1][2]
What unapproved-product warnings actually cover
FDA's concerns page explains that unapproved GLP-1 products, including compounded versions, do not undergo its premarket review for safety, effectiveness and quality. It also recognizes circumstances in which a compounded medicine may address a patient's unmet medical need.[3] Those statements can coexist; compounded and approved are different regulatory statuses.
The page reports adverse events, including hospitalizations, potentially related to dosing errors with compounded injectable semaglutide. FDA cautions that reported events cannot always be attributed directly to a drug rather than other contributing factors.[3] Those reports concern the stated products and circumstances; they do not establish the event rate or causation for every oral product.
FDA also identifies companies selling specified unapproved drugs directly to consumers for human use while falsely labeling them for research. Its warning addresses that conduct and those products, not every legitimate laboratory reagent.[3]
Research materials should not be consumed or self-administered. A sample's identity or purity result, where available, does not establish human safety, effectiveness or suitable absorption. Reconstitution does not supply those missing connections or turn a reagent into an approved medicine. No assumption that every vial is contaminated is needed: the relevant evidence must follow the exact molecule, formulation and human-use context, all the way from the label to the claim.